Xin Lang Cai Jing·2025-11-13 14:56Core Viewpoint - Rongchang Biopharmaceutical (Yantai) Co., Ltd. is revising 13 core governance systems to enhance its governance structure, with 4 of these requiring shareholder approval at an upcoming meeting on December 2, 2025 [1][3][4] Group 1: Board Meeting Details - The board meeting was held on November 13, 2025, with all 9 directors present, confirming compliance with legal and regulatory requirements [2] - The meeting was conducted in a "hybrid" format, combining in-person and remote participation [2] Group 2: Governance System Revisions - The proposed revisions include updates to the following systems: - Related Party Transaction Management - External Guarantee Management - External Investment Management - Fundraising Management - Internal Audit Management - Management of Funds with Related Parties - Market Value Management - Information Disclosure Management - Major Information Internal Reporting - Insider Information Knowledge Person Registration - Management of Shareholding Changes for Directors and Senior Management - Investor Relations Management - Accountability for Major Errors in Annual Report Disclosure [3] - The revisions aim to align with the latest regulatory requirements and improve governance standards, ensuring compliance and protecting shareholder rights [3] Group 3: Upcoming Shareholder Meeting - The third extraordinary general meeting of shareholders is scheduled for December 2, 2025, to discuss the governance system revisions that require shareholder approval [4] - The proposal to hold this meeting received unanimous support from the board [4] - Market analysts view these governance revisions as a significant step towards enhancing internal control systems and meeting capital market regulatory demands [4]